Status:
COMPLETED
A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility:
All Genders
40-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the safety of GW856553 in COPD patients and to assess its affects on their COPD disease after 14 days.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Women of childbearing potential
- Established history of COPD
- Cigarette smoking history greater than 10 pack years
- FEV1 between 40 and 80% of predicted normal for height, age and sex.
- Exclusion criteria:
- Morbidly obese patients (body mass index \>40)
- Hospitalisation or treatment for worsening of COPD in past 6 weeks
- History of increased liver function tests
- hypersensitivity to salbutamol or ipratropium bromide
- Blood pressure \> 155/95
Exclusion
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00392587
Start Date
August 1 2006
Last Update
June 4 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Hanover, Lower Saxony, Germany, 30625
2
GSK Investigational Site
Großhansdorf, Schleswig-Holstein, Germany, 22927
3
GSK Investigational Site
Berlin, State of Berlin, Germany, 14050